WHO Fair Pricing Forum: Watching for Drug Industry Accountability
by Katrina Perehudoff and Jennifer Sellin
Expensive medicines are a ubiquitous challenge from which no government is immune. Excessive price hikes are an urgent human...
Vaccine knowledge needs to be a global public good: Remarks to the World Trade...
Ellen ‘t Hoen, Medicines Law & Policy, at the World Trade Organization-World Health Organization High-Level Dialogue on Expanding COVID-19 Vaccine Manufacturing to Promote Equitable...
Transfer of Technology: New definition and stronger language needed
Statement by Medicines Law & Policy on Article 11, Technology Transfer Intergovernmental Negotiating Body on a Pandemic Accord (INB), Session 12
Delivered at the WHO on...
Urgent collective action to meet the challenge of this pandemic crisis: a coronavirus related...
The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, first described the present coronavirus (COVID-19) outbreak as a pandemic on the 11th...
The Urgency of Compulsory Licensing Provision for Transfer of Technology in the Pandemic Treaty:...
Guest blog by Ronald Eberhard
The Intergovernmental Negotiating Body, established by the World Health Assembly, aims to draft a global pandemic prevention, preparedness, and response...
Wrapping Up 2017 – some noteworthy medicines law and policy events.
2017 was a significant year for access to medicines and other medicines policy related events. Here are a few highlights of the last 12...
Ellen ‘t Hoen named one of the “50 Most Influential People in IP”
For Ellen ‘t Hoen's "fierce" advocacy on access to medicine, and in particular for her efforts under the Covid-19 pandemic to ensure knowledge and...
Intervention at Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or...
The following intervention was delivered by Ellen 't Hoen on 18 March, 2024
Download this statement as a PDF here.
Thank you for the opportunity to...
Strong call for transparency on medicine prices, cost of R&D at WHO Fair Pricing...
“Medical innovation has little social value if most people cannot access its benefits…. this is a global human rights issue,” said Mariângela Simão, Assistant...
Wrapping up 2021 – some noteworthy medicines law and policy events
Welcome to the annual end of the year blog, our highly biased overview of noteworthy events in the field of medicines law and policy....